Regional variations in HIV diagnosis in Japan before and during the COVID-19 pandemic.

Publication date: Mar 01, 2025

The number of people undergoing voluntary HIV testing has abruptly decreased since 2020. The geographical heterogeneity of HIV infection and the impact of COVID-19 on the diagnosis of HIV at regional level are important to understand. This study aimed to estimate the HIV incidence by geographical region and understand how the COVID-19 pandemic influenced diagnosis of HIV. We used an extended back-calculation method to reconstruct the epidemiological dynamics of HIV/AIDS by geographical region. We used eight regions: Tokyo, the capital of Japan, Hokkaido plus Tohoku, Kanto plus Koshinetsu (excluding Tokyo), Hokuriku, Tokai, Kinki, Chugoku plus Shikoku, and Kyushu plus Okinawa. Four different epidemiological measurements were evaluated: (i) estimated HIV incidence, (ii) estimated rate of diagnosis, (iii) number of undiagnosed HIV infections, and (iv) proportion of HIV infections that had been diagnosed. The incidence of HIV/AIDS during the COVID-19 pandemic from 2020 to 2022 increased in all regions except Kanto/Koshinetsu (51. 3 cases/year), Tokyo (183. 9 cases/year), Hokuriku (1. 0 cases/year), and Tokai (43. 1 cases/year). The proportion of HIV infections that had been diagnosed only exceeded 90% in Tokyo (91. 7%, 95% confidence interval (CI): 90. 6, 93. 3), Kanto/Koshinetsu (91. 0%, 95% CI: 87. 3, 97. 8), and Kinki (92. 5%, 95% CI: 90. 4, 95. 9). The proportion of infections that had been diagnosed was estimated at 83. 3% (95% CI: 75. 1, 98. 7) in Chugoku/Shikoku and 80. 5% (95% CI: 73. 9, 91. 0) in Kyusyu/Okinawa. In urban regions with major metropolitan cities, including Tokyo, Kinki, and Kanto/Koshinetsu, the number of undiagnosed HIV infections is substantial. However, the proportion of undiagnosed infections was estimated to be smaller than in other regions. The diagnosed proportion was the lowest in Kyusyu/Okinawa (80. 5%), followed by Chugoku/Shikoku and Hokkaido/Tohoku. The level of diagnosis in those regional prefectures may have been more influenced and damaged by the COVID-19 pandemic than in urban settings.

Open Access PDF

Concepts Keywords
Covid AIDS
Hiv Community
Japan Geographical variations
Therapy Heterogeneity
Incidence
Statistical estimation

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH HIV infection
pathway REACTOME HIV Infection
disease IDO geographical region
disease MESH AIDS
disease MESH infections
drug DRUGBANK Coenzyme M
disease MESH Infectious Diseases
disease IDO history
disease IDO infection
disease IDO immunodeficiency
disease MESH opportunistic infections
disease IDO intervention
disease MESH viral load
disease IDO role
disease IDO country
disease IDO host
disease IDO contact tracing
disease MESH influenza
disease IDO assay
drug DRUGBANK Methionine
disease MESH tumors
disease IDO process
drug DRUGBANK Proline
drug DRUGBANK Ranitidine
drug DRUGBANK Spinosad
disease MESH sexually transmitted infections
disease MESH uncertainty
disease MESH candidiasis
drug DRUGBANK Alpha-1-proteinase inhibitor
disease MESH hemophilia
disease MESH Syndromes
pathway REACTOME Infectious disease
disease IDO infectious disease
drug DRUGBANK Nitroglycerin
disease IDO entity
drug DRUGBANK Dapivirine
drug DRUGBANK Emtricitabine

Original Article

(Visited 1 times, 1 visits today)